###begin article-title 0
Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK
###end article-title 0
###begin p 1
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 1
###begin p 2
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author Contributions:</bold>
Author Contributions: SP, TC, GP, SP, MEE, and SG designed the study, analyzed the data, and contributed to writing the paper.
###end p 2
###begin article-title 3
How Statins May Protect against Alzheimer Disease
###end article-title 3
###begin title 4
Background
###end title 4
###begin p 5
###xml 544 549 536 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Statins are widely used cholesterol-lowering drugs that act by inhibiting HMGCoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Recent evidence suggests that statin use may be associated with a decreased risk for Alzheimer disease, although the mechanisms underlying this apparent risk reduction are poorly understood. One popular hypothesis for statin action is related to the drugs' ability to activate alpha-secretase-type shedding of the alpha-secretase-cleaved soluble Alzheimer amyloid precursor protein ectodomain (sAPPalpha). Statins also inhibit the isoprenoid pathway, thereby modulating the activities of the Rho family of small GTPases-Rho A, B, and C-as well as the activities of Rac and cdc42. Rho proteins, in turn, exert many of their effects via Rho-associated protein kinases (ROCKs). Several cell-surface molecules are substrates for activated alpha-secretase-type ectodomain shedding, and regulation of shedding typically occurs via activation of protein kinase C or extracellular-signal-regulated protein kinases, or via inactivation of protein phosphatase 1 or 2A. However, the possibility that these enzymes play a role in statin-stimulated shedding has been excluded, leading us to investigate whether the Rho/ROCK1 protein phosphorylation pathway might be involved.
###end p 5
###begin title 6
Methods and Findings
###end title 6
###begin p 7
###xml 63 68 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 233 238 229 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 381 386 373 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
We found that both atorvastatin and simvastatin stimulated sAPPalpha shedding from a neuroblastoma cell line via a subcellular mechanism apparently located upstream of endocytosis. A farnesyl transferase inhibitor also increased sAPPalpha shedding, as did a dominant negative form of ROCK1. Most conclusively, a constitutively active ROCK1 molecule inhibited statin-stimulated sAPPalpha shedding.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 81 86 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Together, these data suggest that statins exert their effects on shedding of sAPPalpha from cultured cells, at least in part, by modulation of the isoprenoid pathway and ROCK1.
###end p 9
###begin p 10
The cholesterol-lowering statins seem to have a protective effect against Alzheimer disease. In cultured cells, statins affect cleavage of the amyloid precursor protein via the ROCK kinase. This could explain some of their beneficial effects
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b01">1</xref>
###xml 348 349 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b02">2</xref>
###xml 480 481 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b03">3</xref>
###xml 558 559 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b04">4</xref>
###xml 745 750 721 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 753 754 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b04">4</xref>
###xml 887 888 859 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b05">5</xref>
###xml 889 890 861 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b06">6</xref>
###xml 891 892 863 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b07">7</xref>
###xml 945 946 917 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b05">5</xref>
Alzheimer disease is the leading cause of dementia among the elderly and is characterized by accumulation of extracellular and vascular amyloid in the brain [1]. Amyloid deposits are composed of the amyloid-beta peptide (Abeta), a 4-kDa peptide released during "amyloidogenic" proteolytic processing of the Alzheimer Abeta precursor protein (APP) [2]. APP can also be cleaved by the nonamyloidogenic alpha-secretases, a disintegrin and metalloproteinase 10 (ADAM-10) and ADAM-17 [3], in a reaction that is believed to occur primarily on the plasma membrane [4] and is known as "ectodomain shedding." alpha-Secretase-type ectodomain shedding divides the Abeta domain of APP, thereby generating alpha-secretase-cleaved soluble APP ectodomain (sAPPalpha) [4]. This reaction can be stimulated by activation of protein kinase C (PKC) or extracellular-signal-regulated protein kinases (ERKs) [5,6,7] or by inactivation of protein phosphatase 1 or 2A [5].
###end p 12
###begin p 13
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b08">8</xref>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b09">9</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b10">10</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b11">11</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b12">12</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b13">13</xref>
###xml 566 568 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b12">12</xref>
###xml 569 571 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b14">14</xref>
###xml 632 634 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b15">15</xref>
###xml 635 637 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b16">16</xref>
###xml 745 747 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b17">17</xref>
###xml 748 750 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b18">18</xref>
###xml 211 222 <span type="species:ncbi:10141">guinea pigs</span>
###xml 245 260 <span type="species:ncbi:10090">transgenic mice</span>
###xml 541 544 <span type="species:ncbi:10116">rat</span>
Reports from retrospective analyses suggest that the statin class of cholesterol-lowering HMGCoA reductase inhibitors may lower the risk for Alzheimer disease by as much as 70% [8,9,10,11]. Studies in wild-type guinea pigs and in plaque-forming transgenic mice have demonstrated that chronic statin treatment can attenuate cerebral amyloidosis [12,13], suggesting that statins may exert their risk-reducing effects, at least in part, by modulating APP metabolism. In cell culture, lovastatin and simvastatin decrease the release of Abeta by rat hippocampal neurons [12,14] while activating alpha-secretase-type ectodomain shedding [15,16]. However, the molecular mechanisms by which statins modulate ectodomain shedding remain to be elucidated [17,18].
###end p 13
###begin p 14
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b19">19</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b20">20</xref>
Statin effects on APP metabolism are, to some extent, attributable to cholesterol lowering, but statin actions on APP may also involve cholesterol-independent actions [19]. Reduction in synthesis of mevalonate leads to decreased generation of a number of isoprenoid lipid derivatives. Isoprenoids, such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate, are 15- or 20-carbon lipid moieties. Through the action of farnesyl transferases and type I geranylgeranyl transferases, isoprenoids are attached to the amino acid sequence Cys-Ala-Ala-Xaa ("CAAX") at the C-terminus of the Rho family of GTPases [20]. These posttranslational lipid modifications are essential for attachment of the GTPases to the cytosolic face of intracellular vesicles and/or to the cytosolic leaflet of the plasma membrane, thereby specifying subcellular targets for GTPase action(s).
###end p 14
###begin p 15
###xml 316 318 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b21">21</xref>
###xml 319 321 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b22">22</xref>
###xml 322 324 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b23">23</xref>
###xml 917 919 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b23">23</xref>
###xml 1093 1095 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b24">24</xref>
###xml 1096 1098 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b25">25</xref>
###xml 1099 1101 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b26">26</xref>
###xml 1102 1104 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b27">27</xref>
###xml 1210 1212 1203 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b28">28</xref>
Some members of the Rho GTPase family exert their actions through modulation of protein kinase activities. One of the best characterized is Rho-associated protein kinase 1 (ROCK1, also called ROKbeta). ROCK1 is a serine/threonine kinase with an apparent mass of 160 kDa that can be activated by either RhoA or RhoB [21,22,23]. Structurally, the ROCK1 N-terminus contains the protein kinase domain, while the C-terminus has both a Rho-binding domain and a pleckstrin homology domain, either of which can modulate protein-protein interactions. In the inactive state, the Rho-binding domain and the pleckstrin homology domain form an autoinhibitory loop by binding and blocking the kinase domain at the N-terminus of the molecule. Activation of ROCK1 occurs when a Rho protein binds to the Rho-binding domain, causing a conformational change that opens the kinase domain for the phosphorylation of downstream effectors [23]. Once activated, ROCK1 phosphorylates several substrates, including myosin light chain phosphatase, LIM kinases (Lin11, Isl1, and Mec3), and ezrin-radixin-moesin proteins [24,25,26,27]. ROCK1 has recently been implicated in modifying the site of substrate cleavage by APP gamma-secretase [28], perhaps acting via ROCK1-dependent phosphorylation of a component of the gamma-secretase enzyme complex.
###end p 15
###begin p 16
###xml 60 65 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 314 319 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 523 528 515 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
In the current study, we demonstrate that activation of sAPPalpha shedding from cultured cells by atorvastatin or simvastatin involves isoprenoid-mediated protein phosphorylation. Treatment of cells with a farnesyl transferase inhibitor or expression of a dominant negative (DN) ROCK1 molecule led to enhanced sAPPalpha shedding, supporting the notion that shedding is modulated by the isoprenoid pathway. Transfection with the cDNA for a constitutively active (CA) ROCK1 molecule led to inhibition of statin-activated sAPPalpha shedding. These results raise the possibility that the apparent beneficial effect of statins in the prevention of Alzheimer disease could be, at least in part, mediated by isoprenoid modulation of APP metabolism.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
Reagents
###end title 18
###begin p 19
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b29">29</xref>
###xml 271 276 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 936 938 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b30">30</xref>
###xml 939 941 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b31">31</xref>
###xml 172 177 <span type="species:ncbi:9606">human</span>
###xml 250 255 <span type="species:ncbi:9606">human</span>
The APP C-terminal specific polyclonal antibody 369 [29] was used to detect full-length APP and its C-terminal fragments. Monoclonal antibody 6E10 against residues 1-16 of human Abeta (Signet, Dedham, Massachusetts, United States) was used to detect human holoAPP or sAPPalpha. Anti-ROCK1 antibody was purchased from Chemicon (Temecula, California, United States). Streptavidin-antibody HRP-conjugated C-Myc antibody 9E10, mevalonic acid, arachidonic acid, and phenylarsine oxide were purchased from Sigma (St. Louis, Missouri, United States). Atorvastatin was obtained from Pfizer (Groton, Connecticut, United States), and simvastatin was obtained from LKT Labs (St. Paul, Minnesota, United States). N2 supplement was obtained from Gibco (Carlsbad, California, United States). Sulfo-NHS-LC-Biotin was purchased from Pierce (Rockford, Illinois, United States). CA and DN Myc-tagged ROCK1 vectors were generated as previously described [30,31] and were generous gifts from Liqun Luo (Stanford University). Fugene 6 was purchased from Roche (Basel, Switzerland). Farnesyl transferase inhibitor 1 (FTI-1) was obtained from Biomol (Plymouth Meeting, Pennsylvania, United States). Tumor necrosis factor alpha (TNFalpha) protease inhibitor 2 and Y-27632 were purchased from Calbiochem (San Diego, California, United States). Protein concentration assay kit was purchased from Biorad (Hercules, California, United States). LIVE/DEAD Viability/Cytotoxicity Assay Kits and Amplex Red Cholesterol Assay Kits were purchased from Molecular Probes (Eugene, Oregon, United States).
###end p 19
###begin title 20
Culture Methods and Sample Preparation
###end title 20
###begin p 21
###xml 327 329 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b32">32</xref>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
N2a mouse neuroblastoma cells stably transfected with the Swedish mutant form of APP (SweAPP N2a cells; APP695, 595-596 KM/NL) (gift from G. Thinakaran and S. Sisodia, University of Chicago, Chicago, Illinois, United States) were maintained in DMEM, 10% FBS, and 200 mug/ml G418 in the presence of penicillin and streptomycin [32]. For the 24 h prior to pharmacological treatments, the culture media were changed to N2-supplemented lipid-free medium. In some studies, cells were transfected in N2-supplemented FBS-free medium 48 h before pharmacological treatments. Transfections were carried out using the Fugene reagent, according to the manufacturer's instructions. All treatments were performed in the presence of 1 muM mevalonic acid, unless otherwise specified.
###end p 21
###begin p 22
###xml 156 157 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 341 346 341 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 556 561 552 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 636 642 <span type="species:ncbi:9986">rabbit</span>
###xml 651 656 <span type="species:ncbi:10090">mouse</span>
Cells were lysed in 1% Triton-X/PBS buffer containing 1 X complete proteinase inhibitor cocktail (Roche), sonicated twice for 30 s, and centrifuged at 5,000g for 5 min. Protein concentration in the supernatant was determined using the Biorad Protein Assay kit, following the manufacturer's instructions. For the detection of holoAPP and sAPPalpha, samples were separated in 7.5% polyacrylamide gels, transferred to nitrocellulose, and the proteins detected with either 369 (1:3,000 for holoAPP and C-terminal fragments) or 6E10 (1:1,000 for holoAPP or sAPPalpha), followed by incubation of the transfers with appropriate secondary anti-rabbit or anti-mouse antibodies. For the detection of transfected ROCK1 proteins, samples were immunoprecipitated with 2 mug of anti-Myc antibody, separated in 5% polyacrylamide gels, transferred, and the proteins detected with anti-ROCK1 antibody (1:1,000 dilution).
###end p 22
###begin title 23
Cell-Surface Biotinylation
###end title 23
###begin p 24
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 124 129 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 281 282 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
Cells were plated in a 100-mm dish at a concentration of 5 x 106 cells/dish. After treatment, media were harvested, and sAPPalpha levels were evaluated by immunoblotting as described above. Cells were washed twice in PBS and then incubated with Sulfo-NHS-LC-Biotin for 30 min at 4 oC. Biotinylation reactions were terminated by one wash in Tris followed by two washes in PBS. Cells were lysed in 1% Triton-X/PBS buffer containing protease inhibitor cocktail as indicated above. Lysates were immunoprecipitated with 3 mul of whole 369 antibody serum and 30 mul of protein A beads. After washing twice with 1% Triton/PBS, and then twice with PBS, samples were boiled in sample buffer for 3 min, separated in a 7.5% polyacrylamide gel, and transferred to nitrocellulose. The biotinylated proteins were detected using streptavidin HRP polymer (1:10,000 dilution).
###end p 24
###begin title 25
Viability/Cytotoxicity Assays
###end title 25
###begin p 26
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
Cells were plated in an eight-well slide at a concentration of 1 x 104 cells/well. After treatments as indicated, LIVE/DEAD assays were performed following the manufacturer's instructions (Molecular Probes).
###end p 26
###begin title 27
Cholesterol Assays
###end title 27
###begin p 28
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b16">16</xref>
Cholesterol levels in cell lysates were measured using Amplex Red following the manufacturer's instructions (Molecular Probes). We have previously demonstrated that standard doses of either simvastatin or atorvastatin reduce cholesterol levels in N2a cells by 65%-67% [16].
###end p 28
###begin title 29
Quantification and Statistical Analysis
###end title 29
###begin p 30
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Quantification of protein bands was performed using the UVP Bioimaging System, and statistical analysis was performed on paired observations using the Student's t test.
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
###xml 27 32 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Atorvastatin Activates sAPPalpha Shedding at a Subcellular Site Upstream of Endocytosis from the Plasma Membrane
###end title 32
###begin p 33
###xml 39 41 39 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b16">16</xref>
###xml 89 94 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 184 189 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
We confirmed our previous observation [16] that atorvastatin produces an increase in sAPPalpha shedding that is dose-dependent, reaching a maximum effect at 5 muM. The increase in sAPPalpha shedding is accompanied by a corresponding increase in levels of the nonamyloidogenic APP alpha-C-terminal fragment (C83; data not shown).
###end p 33
###begin p 34
###xml 317 322 317 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 475 483 471 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g001">Figure 1</xref>
###xml 496 501 492 493 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 550 551 542 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 652 657 644 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 1038 1040 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b15">15</xref>
###xml 1041 1043 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b33">33</xref>
###xml 1260 1262 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b34">34</xref>
In order to refine our localization of the subcellular target of statin action, we evaluated the steady-state levels of cell-surface APP (csAPP) in the absence or presence of statins. After drug treatments, cells were subjected to the surface biotinylation protocol. Cells and media were harvested, and levels of sAPPalpha, holoAPP, and csAPP were measured. Treatment with atorvastatin increased csAPP by approximately 1.6-fold, similar to the effect of the drug on holoAPP (Figure 1), while sAPPalpha shedding was increased by approximately 7-fold (p < 0.05). Since csAPP levels were only slightly raised in the same statin-treated cells in which sAPPalpha shedding was dramatically increased, we interpret this disparity to indicate that the effector of statin-stimulated shedding is probably intrinsic to the plasma membrane. In other studies, the plasma membrane has been proposed to be, or to contain, the statin target. For example, statins have been proposed to cause co-localization of alpha-secretase and APP within lipid rafts [15,33]; statins might also induce modification of the structure and activity of a protein in the plasma membrane alpha-secretase complex, perhaps in an action similar to how statins bind and "lock" cell-surface integrins [34].
###end p 34
###begin p 35
###xml 275 277 275 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 449 454 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 456 457 452 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b05">5</xref>
###xml 458 460 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b29">29</xref>
###xml 867 868 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 950 951 946 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 966 967 962 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1096 1101 1092 1093 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 1434 1439 1426 1427 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
A pulse-chase protocol was also used to study post-transcriptional regulation of APP metabolsm by statins (data not shown). This protocol avoids any confound that might arise because of altered APP transcription. Pulse-chase studies were performed using a 10-min pulse with [35S]methionine followed by various chase times from 0 to 120 min. Typical maturation and half-life of mature cellular holoAPP were observed, as was subsequent release of sAPPalpha [5,29]. In the presence of either atorvastatin or simvastatin, the time course of maturation and release perfectly paralleled that observed in the absence of either drug, except that the fractional content of cellular mature holoAPP was approximately 2-fold greater in the presence of drug (i.e., at 15 or 75 min chase, mature APP in the presence of statin was approximately 310% of the level of immature APP at t = 0 versus a control [vehicle treatment] of 150% of the level of immature APP at t = 0; also, at t = 30 min, the relative percent values for drug versus vehicle were 380% and 200%, respectively). Fold increases in released sAPPalpha in the same experiments were approximately 3- to 4-fold (2.0 arbitrary units versus 5.5-8.0 arbitrary units at 120 min for atorvastatin and simvastatin, respectively). Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular mature holoAPP and causes retarded conversion of mature holoAPP to sAPPalpha. This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of mature cellular holoAPP.
###end p 35
###begin p 36
###xml 370 375 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 637 642 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 917 919 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b35">35</xref>
###xml 920 922 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b36">36</xref>
Instead, the pattern that we observed raises the possibility that statins, presumably via isoprenoids (given the reversibility with mevalonate), as discussed in the next section, may alter sorting of cellular holoAPP, diverting holoproteins away from terminal degradation in the endosomal/lysosomal pathway and into the constitutive secretory pathway that generates sAPPalpha. However, the fold effect on reduced intracellular turnover in the endosomal/lysosomal pathway (or sorting out of the endosomal/lysosomal pathway and into the constitutive secretory/shedding pathway) is apparently insufficient to explain the fold effect on sAPPalpha generation (2-fold for the former, vs 3- to 4-fold for the latter), indicating a contribution from a downstream site in the processing pathway. When these results are taken together with independent work on regulated shedding of transforming growth factor alpha (TGFalpha) [35,36], a parsimonious explanation is that an important target for activation of ectodomain shedding is probably located at the plasma membrane or downstream of APP residence at the plasma membrane.
###end p 36
###begin p 37
###xml 178 183 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 197 198 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b04">4</xref>
###xml 199 201 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b35">35</xref>
###xml 202 204 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b36">36</xref>
###xml 205 207 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b37">37</xref>
###xml 290 292 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b38">38</xref>
The identification of the regulatory components of the ectodomain shedding machinery have been long-sought in other studies employing phorbol esters to stimulate shedding of sAPPalpha or TGFalpha [4,35,36,37]. Munc-13 has recently been implicated as a phorbol target in regulated shedding [38]. In our opinion, this molecule is rather unlikely to play a major role in shedding regulation, given the specificity of Munc-13 effects for phorbols and the generalization of the regulated shedding phenomenon to include activation by protein phosphatase inhibitors and neurotransmitters. Neither of these would be predicted to act via the phorbol-binding C1 domain of Munc-13.
###end p 37
###begin p 38
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b39">39</xref>
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NPXY</italic>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b40">40</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b41">41</xref>
###xml 203 208 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 533 541 525 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g002">Figure 2</xref>
###xml 619 624 611 612 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 744 749 732 733 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 916 917 900 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1138 1143 1122 1123 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 1269 1277 1241 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g002">Figure 2</xref>
###xml 1472 1474 1440 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b16">16</xref>
Sisodia and colleagues [39] demonstrated that arrest of APP endocytosis from the plasma membrane by deletion of its NPXY clathrin-coated vesicle targeting sequence [40,41] can dramatically stimulate sAPPalpha shedding, presumably by extending the half-life of co-localized alpha-secretase and APP on the plasma membrane. In order to exclude the possible contribution of altered endocytosis to statin-stimulated shedding, we evaluated the effect of phenylarsine oxide (PO), an inhibitor of endocytosis, on statin-stimulated shedding (Figure 2). Treatment with either atorvastatin, simvastatin, or PO alone increased sAPPalpha shedding, as expected. Co-treatment of cells with PO plus either atorvastatin or simvastatin caused stimulation of sAPPalpha shedding to levels greater than the maximal levels of shedding achievable with inhibition of endocytosis using PO alone or with maximal doses of either statin alone (p < 0.05). The additivity of statin- and PO-stimulated shedding is consistent with the hypothesis that statins act at or near the plasma membrane, prior to internalization of csAPP. Under all circumstances, stimulated sAPPalpha shedding was completely blocked using TNFalpha protease inhibitor 2, a standard alpha-secretase/metalloproteinase inhibitor (Figure 2). We interpret this as an indication that the statin-induced alpha-cleavage of APP is probably mediated by one of the molecules usually associated with the phenomenon, i.e., ADAM-10 or ADAM-17 [16].
###end p 38
###begin title 39
###xml 55 60 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Compounds that Modulate Isoprenoid Levels Activate sAPPalpha Shedding
###end title 39
###begin p 40
###xml 189 194 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 241 246 237 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 305 310 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 392 400 380 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g003">Figure 3</xref>
###xml 402 403 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 557 562 545 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 564 572 548 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g003">Figure 3</xref>
As discussed above, there is an established relationship between statins and isoprenoid-modulated protein phosphorylation. We therefore tested the effects of FTI-1 on statin-stimulated sAPPalpha shedding. FTI-1 increased the shedding of sAPPalpha, but the combination of a statin plus FTI-1 increased sAPPalpha shedding to levels greater than those achievable by using either compound alone (Figure 3; p < 0.05). In the same experiment, levels of holoAPP were modestly increased but, again, to an extent insufficient to account for the increase in shed sAPPalpha (Figure 3).
###end p 40
###begin p 41
###xml 306 311 304 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 461 466 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 525 530 514 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 740 748 724 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g004">Figure 4</xref>
To test whether statin-activated shedding might be attributable to a metabolite downstream of HMGCoA reductase, cells were treated with 1 muM simvastatin, 5 muM FTI-1, and a series of concentrations of mevalonic acid. Since FTI-1 acts downstream of HMGCoA reductase, the stimulatory effect of FTI-1 on sAPPalpha shedding would not be predicted to be modified by mevalonate supplementation. Low doses (<1 muM) of mevalonic acid did not affect statin-induced sAPPalpha shedding, but complete inhibition of statin-activated sAPPalpha shedding was achieved with higher doses of mevalonic acid (100 muM). As predicted, the shedding observed following treatment with FTI-1 was not inhibited by any of the concentrations of mevalonic acid tested (Figure 4). These data are consistent with a role for isoprenoids in statin control of APP metabolism in cultured cells.
###end p 41
###begin title 42
###xml 51 56 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Expression of ROCK-Related Molecules Modulates sAPPalpha Shedding in a Bidirectional Manner
###end title 42
###begin p 43
###xml 185 193 185 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g005">Figure 5</xref>
###xml 243 248 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 341 346 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 413 421 405 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g005">Figure 5</xref>
###xml 423 424 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 506 511 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 575 583 563 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g005">Figure 5</xref>
###xml 585 586 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 705 710 693 694 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 806 814 790 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g006">Figure 6</xref>
###xml 861 866 845 846 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 983 988 963 964 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Since many isoprenoid-mediated Rho effects converge on ROCKs, we next transfected N2a cells with cDNAs encoding either green fluorescent protein (GFP) (control), CA ROCK1, or DN ROCK1 (Figure 5). Simvastatin caused a typical activation of sAPPalpha shedding from GFP-transfected cells. When CA ROCK1 was introduced, however, shedding of sAPPalpha from both untreated and simvastatin-treated cells was diminished (Figure 5; p < 0.05 versus GFP control). Conversely, DN ROCK1 alone activated shedding of sAPPalpha. Cellular levels of holoAPP were not affected by transfection (Figure 5; p < 0.05 versus GFP control). In studies aimed at independent confirmation of the involvement of ROCK activation in sAPPalpha shedding, we treated SweAPP N2a cells with arachidonic acid, an activator of ROCK. As shown in Figure 6, arachidonic acid reduced the shedding of sAPPalpha without altering levels of holoAPP. Based on this series of results, we concluded that both basal and activated sAPPalpha shedding from cultured cells are controlled by ROCK activity.
###end p 43
###begin p 44
###xml 145 150 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 192 197 187 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 530 532 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b23">23</xref>
In some experiments, cells were treated with Y-27632 (10 nM to 50 muM), a compound that can inhibit ROCKs. Y-27632 showed no effect on basal sAPPalpha release and blocked statin-activated sAPPalpha shedding (data not shown). This result was unexpected in light of the effects of DN ROCK1. Given the internally consistent actions of DN ROCK1 and CA ROCK1, as well as the results employing either FTI-1 or arachidonate, we concluded that the Y-27632 result might be due to inhibition by Y-27632 of protein kinases other than ROCK1 [23]. The possibility was also considered that cytotoxicity of Y-27632 for the central vacuolar pathway might explain the disparity between the effects of DN ROCK1 and those of Y-27632, but neither impairment of intracellular APP maturation nor increased apoptosis as measured by LIVE/DEAD assay were apparent following Y-27632 treatment (data not shown). Ultimately, we were unable to document any explanation for the disparate results of Y-27632 and DN ROCK1.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b20">20</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b42">42</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b20">20</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b42">42</xref>
###xml 395 403 395 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g007">Figure 7</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b23">23</xref>
The isoprenoid pathway involves lipid modification of various members of the Rho family of small GTPases by the addition of either farnesyl or geranylgeranyl moieties [20,42]. Isoprenylation serves to target the GTPases to the proper organelle membrane, where their actions often relate to cytoskeletal dynamics and/or vesicle trafficking [20,42]. ROCKs are important downstream targets of Rho (Figure 7), catalyzing the phosphorylation of effector phosphoprotein substrates [23]. The foregoing data indicate that statin-induced activation of APP shedding in cultured cells involves the Rho/ROCK pathway. More specifically, the data indicate that ROCK1 activation blocks the effects of statins on APP ectodomain shedding, while ROCK1 blockade alone can mimic the effect of statins on APP shedding. By extension, these data predict that application of statins to neurons might directly or indirectly inhibit ROCK1 activity. Evaluation of this possibility will be the subject of future investigation.
###end p 46
###begin p 47
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b43">43</xref>
###xml 130 135 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 307 309 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b35">35</xref>
###xml 310 312 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b36">36</xref>
###xml 325 327 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b44">44</xref>
###xml 541 542 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b02">2</xref>
###xml 543 545 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b29">29</xref>
###xml 546 548 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b45">45</xref>
###xml 843 844 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b04">4</xref>
###xml 845 847 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b39">39</xref>
###xml 997 998 981 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b03">3</xref>
###xml 999 1001 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b46">46</xref>
The first evidence that APP might be a substrate for ectodomain shedding was provided by Weidemann et al. [43] who identified sAPPalpha in the cerebrospinal fluid and blood. This aspect of APP metabolism bears resemblance to the proteolytic signal transduction pathways involved in processing pro-TGFalpha [35,36] and Notch [44]. In the case of Notch, the process is set in motion by the binding of a ligand to the Notch ectodomain, triggering its release (shedding). For APP, intracellular signal transduction appears to be more important [2,29,45]. In early studies, the existence of the shed ectodomain of APP was used to deduce the existence of the proteolytic activity designated alpha-secretase, which has the unusual specificity of cleaving its substrates at a proscribed distance from the extracellular leaflet of the plasma membrane [4,39]. Ultimately, the integral cell-surface metalloproteinases ADAM-10 and ADAM-17/TACE were found to underlie alpha-secretase-type ectodomain shedding [3,46].
###end p 47
###begin p 48
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b39">39</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b43">43</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b47">47</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b48">48</xref>
###xml 462 463 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b05">5</xref>
###xml 559 560 559 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b05">5</xref>
###xml 760 765 753 754 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 939 941 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b49">49</xref>
###xml 1006 1008 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b50">50</xref>
###xml 1015 1020 994 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 1029 1033 1004 1005 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</sub>
###xml 1065 1070 1037 1038 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 1117 1122 1082 1083 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 1176 1180 1137 1138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</sub>
###xml 1226 1231 1184 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1393 1398 1351 1352 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 1466 1470 1420 1421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</sub>
###xml 1472 1474 1423 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b51">51</xref>
Why is APP a substrate for ectodomain shedding? To answer this question requires contemplation of the physiological function of APP. APP is a type 1 integral protein that is subjected to a host of post-translational processing events, including N- and O-glycosylation, tyrosyl sulfation, phosphorylation, and proteolysis [39,43,47,48]. Most (60%-80%) newly synthesized APP is subjected to terminal intracellular degradation that generates no discrete fragments [5]. A smaller fraction of APP molecules (approximately 20% in PC12 cells under basal conditions [5]) undergoes ectodomain shedding catalyzed by either the alpha-secretase (nonamyloidogenic) or beta-secretase (potentially amyloiodgenic) pathway. When PKC is activated, the stoichiometry of shed sAPPalpha rises from 2 mol shed per 10 mol synthesized to 4 mol shed per mole synthesized. Most of this shedding is catalyzed by the alpha-secretase pathway, but a trace amount (<5% [49]) is catalyzed by beta-secretase/beta-site APP cleaving enzyme [50]. sAPPalpha and sAPPbeta differ by the inclusion in sAPPalpha of the first 16 residues of Abeta. Unlike sAPPalpha, which is generated at the plasma membrane, most sAPPbeta is probably generated by cleavage within the trans-Golgi network and endocytic pathway vesicles. HoloAPP levels are likely limiting at one or more sorting steps in the late secretory pathway, since activated sAPPalpha shedding is apparently accompanied by diminished generation of sAPPbeta [51].
###end p 48
###begin p 49
###xml 33 38 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 317 322 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 420 422 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b52">52</xref>
###xml 540 542 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b53">53</xref>
###xml 609 611 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b54">54</xref>
###xml 689 691 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b55">55</xref>
###xml 694 698 <span type="species:ncbi:10090">Mice</span>
What is the function of shed sAPPalpha? Again, from other molecules, we know that shedding can serve important cellular functions by releasing diffusible ligands from their membrane-bound precursors (e.g., TGFalpha and TNFalpha) or by terminating intercellular signaling (e.g., Notch). A popular model holds that sAPPalpha may function as a neurotrophic and/or neuroprotective factor, and may promote neurite outgrowth [52]. More recent evidence suggests that released APP derivatives modulate efficacy of neurotransmission at the synapse [53]. Targeted deletion of APP has not revealed a striking phenotype [54], presumably because of functional redundancy supplied by APP-like proteins [55]. Mice with double and triple null mutations in various combinations of APP, APP-like protein 1, and APP-like protein 2 are now being created, in search of evidence for a definitive function for APP.
###end p 49
###begin p 50
###xml 16 18 16 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b56">56</xref>
Cao and Sudhof [56] have recently discovered that the APP C-terminal fragment generated by alpha- or beta-secretase is itself cleaved to release Abeta and an APP intracellular domain (AICD) that diffuses into the nucleus, possibly acting there as a transcription factor. The pathway leading to AICD must be initiated by ectodomain shedding: holoAPP cannot directly give rise to AICD. Therefore, one important function for alpha- and/or beta-secretase processing of APP may be the eventual generation of AICD. Our results suggest that Rho/ROCK signaling provides modulation of basal and stimulated alpha-secretase activity. It will now be important to dissect pathways upstream of Rho/ROCK signaling in order to identify the intracellular and intercellular events that participate in Rho/ROCK regulation of alpha-secretase under physiological and pathological conditions.
###end p 50
###begin p 51
###xml 109 111 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b57">57</xref>
###xml 185 187 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b15">15</xref>
###xml 575 576 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b08">8</xref>
###xml 577 578 567 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b09">9</xref>
###xml 579 581 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b10">10</xref>
###xml 582 584 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b11">11</xref>
###xml 961 962 939 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b05">5</xref>
###xml 963 965 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b29">29</xref>
###xml 976 977 954 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b07">7</xref>
###xml 1040 1042 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b29">29</xref>
###xml 1148 1150 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b16">16</xref>
The potential role of cholesterol in alpha-secretase-mediated shedding was discovered by Bodovitz and Klein [57] who used beta-cyclodextrin to lower cellular cholesterol. Kojro et al. [15] confirmed this observation, using not only beta-cyclodextrin but also lovastatin to lower cellular cholesterol. These investigators proposed that elevated ADAM-10 activity and protein levels contributed to these effects. These basic observations dovetailed with emerging epidemiological evidence that administration of statins might lead to a diminished incidence of Alzheimer disease [8,9,10,11]. Despite this, however, the association of statins and cholesterol levels with activated alpha-secretase-mediated shedding of the APP ectodomain was unexpected and not readily explicable by existing knowledge regarding regulation of alpha-secretase activity. The best characterized regulation of alpha-secretase processing typically involves protein phosphorylation via PKC [5,29] or ERKs [7] or protein dephosphorylation by protein phosphatase 1 or 2A [29]. We recently excluded the possibility that either PKC or ERK plays a role in statin-activated shedding [16], raising the possibility that other protein phosphorylation signaling pathways might link statins and/or cholesterol to alpha-secretase activation.
###end p 51
###begin p 52
###xml 16 18 16 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b58">58</xref>
###xml 347 349 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b28">28</xref>
###xml 882 887 863 864 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Maillet et al. [58] implicated the Rho pathway in modulation of alpha-secretase activity while dissecting the activated shedding process that accompanies serotonergic signal transduction. These investigators discovered that Rap1 acts through Rac to modulate alpha-secretase processing of APP. Soon thereafter, ROCK1 was discovered by Zhou et al. [28] to modulate a downstream processing step in APP metabolism that involves presenilin/gamma-secretase-mediated proteolysis of APP C-terminal fragments C99 and C83. These investigators discovered that activation of ROCK1 may account for how nonsteroidal anti-inflammatory drugs specify the scissile bond within the APP transmembrane domain that is cleaved by presenilin/gamma-secretase to generate the C-terminus of Abeta. Based on these reports, we asked whether the Rho/ROCK pathway might play a role in controlling shedding of sAPPalpha following statin application.
###end p 52
###begin p 53
###xml 314 322 306 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g007">Figure 7</xref>
###xml 394 396 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b59">59</xref>
###xml 748 750 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b60">60</xref>
###xml 914 922 906 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g004">Figure 4</xref>
###xml 1018 1026 1010 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0020018-g007">Figure 7</xref>
###xml 1436 1441 1428 1429 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
CA ROCK1 and DN ROCK1 molecules yielded direct and complementary evidence that ROCK1 was indeed a candidate for modulation of statin-activated alpha-secretase action. Further, we were able to demonstrate that alpha-secretase activity could be modulated by molecules further upstream in the isoprenoid pathway (see Figure 7). FTI-1, an inhibitor of farnesyl transferase also known as L-744,832 [59], mimicked and potentiated statin-activated shedding, presumably by blocking transfer of isoprenoid moieties to a Rho protein by farnesyl transferase, and thereby decreasing Rho activity. However, FTI-1 treatment can also increase the level of geranylgeranylated isoforms of certain Rho proteins, e.g., the inhibitory geranylgeranylated RhoB protein [60]. In further support of a role for isoprenoids, we were able to demonstrate that supplementation of cells with mevalonate abolished statin-activated shedding (see Figure 4). Statins block HMGCoA reductase generation of mevalonate from 3-hydroxy-methyl-glutarate (see Figure 7). Therefore, the addition of mevalonate would be predicted to antagonize statin action via the isoprenoid pathway, by relieving statin-induced mevalonate deficiency. As predicted by this model, we observed that statin-activated shedding was abolished by adding mevalonate. Taken together, these results suggest the existence of a reciprocal relationship between isoprenoid-mediated Rho/ROCK signaling and sAPPalpha shedding, i.e., activation of ROCK1 blocks basal and stimulated shedding while ROCK1 inhibition apparently relieves a tonic negative influence exerted on shedding by ROCK1 activity.
###end p 53
###begin p 54
###xml 521 523 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b61">61</xref>
###xml 524 526 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b62">62</xref>
As in PKC- and ERK-activated shedding, the ROCK1 substrate effector molecule or molecules that regulate proteolysis by ADAMs remain to be identified. The cytoplasmic domains of both APP and ADAM-17 have been evaluated as candidates for important targets of protein phosphorylation during the regulated shedding process, but neither "substrate activation" nor "enzyme activation" appears to explain the phenomenon, i.e., phosphorylation of neither APP nor ADAM-17 dramatically increases the efficiency of alpha-secretion [61,62], indicating that activation is more indirect.
###end p 54
###begin p 55
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b36">36</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b63">63</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b64">64</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b65">65</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b36">36</xref>
Our data using statins and PO localize the mediator of statin-activated shedding to the plasma membrane, upstream of endocytosis, as appears to be the case for PKC-activated shedding [36,63,64,65]. Similar conclusions were drawn by Bosenberg and colleagues [36] who used streptolysin-porated cells and N-ethylmaleimide to demonstrate that reconstitution of activated shedding of TGFalpha from CHO cells does not require membrane trafficking and apparently occurs on the plasma membrane. These results suggest that a tightly membrane-associated regulatory subunit of the alpha-secretase complex is likely to be the key phosphoprotein that mediates alpha-secretase activity as a function of its state of phosphorylation by PKC and perhaps also ERK and ROCK1. The molecular identity of this phosphoprotein remains unknown.
###end p 55
###begin p 56
###xml 120 122 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b66">66</xref>
###xml 241 243 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b67">67</xref>
###xml 295 297 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b68">68</xref>
###xml 459 461 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b69">69</xref>
###xml 542 544 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b13">13</xref>
###xml 1078 1079 1044 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b03">3</xref>
###xml 353 368 <span type="species:ncbi:10090">transgenic mice</span>
###xml 525 540 <span type="species:ncbi:10090">transgenic mice</span>
###xml 605 610 <span type="species:ncbi:9606">human</span>
alpha-Secretase activation is a potential therapeutic strategy for modifying cerebral amyloidosis in Alzheimer disease [66]. This proposal is supported by recent evidence that either genetic modification of ADAM-10/alpha-secretase activity [67] or administration of bryostatin, a PKC activator [68], can modulate levels of brain Abeta in plaque-forming transgenic mice. alpha-Secretase activation may explain how statins lower the risk for Alzheimer disease [69], since atorvastatin diminishes Abeta burden in plaque-forming transgenic mice [13]. If alpha-secretase stimulation is to be truly viable as a human clinical intervention, it will be essential to assess the possibility that enhanced APP ectodomain shedding might incur mechanism-based toxicity (analogous to the concerns currently surrounding gamma-secretase inhibitors). Along this line, extension of this work to other shed proteins will be important to determine the impact of enhanced shedding via ADAM proteinases on other substrates of those proteinases, including Notch, pro-TGFalpha, pro-TNFalpha, and CD44 [3].
###end p 56
###begin p 57
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b70">70</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b71">71</xref>
###xml 535 537 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b72">72</xref>
###xml 999 1001 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b73">73</xref>
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 862 867 <span type="species:ncbi:9606">human</span>
Preliminary results from a pilot proof-of-concept using atorvastatin in a human clinical treatment trial are consistent with the proposed beneficial effects of this class of compounds [70]. Since atorvastatin has low blood-brain barrier permeability [71], this beneficial effect, if attributable to Abeta lowering, must be due to altered Abeta metabolism in the periphery. Reduction in levels of free Abeta in the circulation has been demonstrated to lead to diminution in brain plaque burden following active or passive immunization [72]. It is conceivable that, if statins lower circulating Abeta, this effect could secondarily cause diffusion of central nervous system interstitial Abeta down its concentration gradient and into the cerebrospinal fluid and circulation, from which it is cleared. To date, however, this mechanism is not supported by data from human clinical trials, where statin administration has shown no consistent effect on levels of circulating or cerebrospinal fluid Abeta [73].
###end p 57
###begin p 58
###xml 372 374 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0020018-b67">67</xref>
The results reported here point to several areas for additional investigation. As described above, the key substrate or substrates linking cytoplasmic protein phosphorylation to intralumenal or cell-surface protelysis remain to be identified. Nonetheless, alpha-secretase activation has been validated as a viable therapeutic strategy for modulating cerebral amyloidosis [67]. Identification of the role of the Rho/ROCK pathway in regulating alpha-secretase provides a new avenue for its therapeutic activation, even though the potential relevance of atorvastatin-mediated ROCK1 inhibition in neurons may not explain the apparent clinical benefits of the drug. Still, if the reported disease-modifying effect of atorvastatin is confirmed in the National Institute on Aging's large, multi-center trial of simvastatin, one or more compounds of this class may be among the first disease-modifying compounds approved by the Food and Drug Administration for slowing the progression of Alzheimer disease.
###end p 58
###begin title 59
Supporting Information
###end title 59
###begin title 60
Accession Numbers
###end title 60
###begin p 61
The GenBank () accession numbers for the proteins discussed in this paper are ROCK1 (NP_005397) and APP695, 595-596 KM/NL (NP_958817).
###end p 61
###begin title 62
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Summary
###end title 62
###begin title 63

###end title 63
###begin title 64
Background
###end title 64
###begin p 65
###xml 195 201 <span type="species:ncbi:9606">people</span>
###xml 242 248 <span type="species:ncbi:9606">people</span>
Large-scale studies have found a link between taking cholesterol-lowering drugs called statins and a decreased risk of developing Alzheimer disease. But it is not clear why statins might protect people from getting the disease. The brains of people who have died from Alzheimer disease show remnants of damaged cells called "tangles" as well as "amyloid plaques" in the spaces between the cells. These plaques are mostly made up of collections of a protein called amyloid-beta. It is the buildup of this protein that is thought to cause the brain damage and dementia associated with Alzheimer disease. The protein itself is formed when another, larger protein called APP (Alzheimer amyloid-beta peptide precursor protein) is broken down (or cleaved). There are two ways in which APP can be broken down. "Bad cleavage" releases the toxic amyloid-beta, whereas "good cleavage" destroys it. When researchers gave statins to animals over a long period of time, they found that statins could slow down the formation of amyloid plaques. From the animal experiments, it seemed that statins somehow caused more good cleavage to occur.
###end p 65
###begin title 66
Why Was This Study Done?
###end title 66
###begin p 67
This study examined how statins can affect APP cleavage.
###end p 67
###begin title 68
What Did the Researchers Do?
###end title 68
###begin p 69
They studied cells to see which of the players known to be involved in APP cleavage were affected by statin.
###end p 69
###begin title 70
What Did They Find?
###end title 70
###begin p 71
Statin's ability to promote "good cleavage" of APP involves a molecular pathway called the Rho/ROCK1 pathway. It seems that when ROCK1 is active, less good cleavage takes place. But in the presence of statins, ROCK1 is less active, shifting the balance toward good cleavage. Consistent with this, when the scientists blocked the Rho/ROCK1 pathway, they saw the good cleavage pattern even without statin.
###end p 71
###begin title 72
###xml 24 32 <span type="species:ncbi:9606">Patients</span>
What Does This Mean for Patients?
###end title 72
###begin p 73
Inhibition of the Rho/ROCK1 pathway could explain some of the beneficial effects of statins against Alzheimer disease. And the pathway itself seems worth more research to see whether it might be a good target for new ways to prevent and treat Alzheimer disease.
###end p 73
###begin title 74
What Are the Limitations of the Study?
###end title 74
###begin p 75
Statins are likely to influence the risk for Alzheimer disease by several different pathways, and future studies will need to show how important this particular pathway is in the overall picture. Moreover, studies like this one are by necessity done in cells under carefully controlled laboratory conditions and still a long way from the development of safe and effective drugs.
###end p 75
###begin title 76
More Information Online
###end title 76
###begin p 77
Factsheet on statins from the Alzheimer's Association:
###end p 77
###begin p 78
General information at the Alzheimer's Disease Education and Referral Center at the United States National Institute of Aging:
###end p 78
###begin p 79
Homepage of Alzheimer's Disease International, an umbrella organization of Alzheimer disease associations around the world:
###end p 79
###begin p 80
The authors would like to thank the United States Public Health Service for support of salaries, supplies, and publication costs, via National Institute on Aging grant AG10491 to SG, National Institute on Neurological Diseases and Stroke grants NS42017 to SG and NS45913 to SP, and National Cancer Institute grant CA100123 to GCP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 80
###begin title 81
References
###end title 81
###begin article-title 82
Uber eine eigenartige Erkrankung der Hirnrinde
###end article-title 82
###begin article-title 83
Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease
###end article-title 83
###begin article-title 84
Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor
###end article-title 84
###begin article-title 85
Beta-amyloid precursor protein cleavage by a membrane-bound protease
###end article-title 85
###begin article-title 86
Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein
###end article-title 86
###begin article-title 87
Secretory processing of the Alzheimer amyloid beta/A4 protein precursor is increased by protein phosphorylation
###end article-title 87
###begin article-title 88
Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway
###end article-title 88
###begin article-title 89
Statins and the risk of dementia
###end article-title 89
###begin article-title 90
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
###end article-title 90
###begin article-title 91
###xml 70 75 <span type="species:ncbi:9606">women</span>
Serum lipoprotein levels, statin use, and cognitive function in older women
###end article-title 91
###begin article-title 92
###xml 102 108 <span type="species:ncbi:9606">people</span>
Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people
###end article-title 92
###begin article-title 93
Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo
###end article-title 93
###begin article-title 94
Statin therapy for Alzheimer's disease: Will it work?
###end article-title 94
###begin article-title 95
Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons
###end article-title 95
###begin article-title 96
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10
###end article-title 96
###begin article-title 97
Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding
###end article-title 97
###begin article-title 98
Alzheimer's disease: The cholesterol connection
###end article-title 98
###begin article-title 99
Cholesterol and the biology of Alzheimer's disease
###end article-title 99
###begin article-title 100
A tale of two statins: The effects of lovastatin and simvastatin on APP metabolism [abstract]
###end article-title 100
###begin article-title 101
Protein prenylation: Molecular mechanisms and functional consequences
###end article-title 101
###begin article-title 102
The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase
###end article-title 102
###begin article-title 103
Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho
###end article-title 103
###begin article-title 104
Rocks: Multifunctional kinases in cell behaviour
###end article-title 104
###begin article-title 105
Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)
###end article-title 105
###begin article-title 106
Rho-associated kinase ROCK1 activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop
###end article-title 106
###begin article-title 107
Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase
###end article-title 107
###begin article-title 108
RhoA and Rho kinase-dependent phosphorylation of moesin at Thr-558 in hippocampal neuronal cells by glutamate
###end article-title 108
###begin article-title 109
Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho
###end article-title 109
###begin article-title 110
Processing of Alzheimer beta/A4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation
###end article-title 110
###begin article-title 111
p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions
###end article-title 111
###begin article-title 112
Small GTPases Rac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons
###end article-title 112
###begin article-title 113
Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo
###end article-title 113
###begin article-title 114
Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts
###end article-title 114
###begin article-title 115
Locking a leukocyte integrin with statins
###end article-title 115
###begin article-title 116
Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process
###end article-title 116
###begin article-title 117
Activated release of membrane-anchored TGF-alpha in the absence of cytosol
###end article-title 117
###begin article-title 118
Transforming growth factor-alpha and beta-amyloid precursor protein share a secretory mechanism
###end article-title 118
###begin article-title 119
Munc13-1-mediated vesicle priming contributes to secretory amyloid precursor protein processing
###end article-title 119
###begin article-title 120
Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing
###end article-title 120
###begin article-title 121
Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42
###end article-title 121
###begin article-title 122
X11alpha modulates secretory and endocytic trafficking and metabolism of amyloid precursor protein: Mutational analysis of the YENPTY sequence
###end article-title 122
###begin article-title 123
Rab geranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys
###end article-title 123
###begin article-title 124
Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein
###end article-title 124
###begin article-title 125
###xml 105 115 105 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 105 115 <span type="species:ncbi:7227">Drosophila</span>
Cell-autonomous role of Notch, an epidermal growth factor homologue, in sensory organ differentiation in Drosophila
###end article-title 125
###begin article-title 126
Proteolytic processing of APP by secretases does not require cell-surface transport
###end article-title 126
###begin article-title 127
Implication of APP secretases in Notch signaling
###end article-title 127
###begin article-title 128
Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca2+/calmodulin-dependent protein kinase II
###end article-title 128
###begin article-title 129
The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway
###end article-title 129
###begin article-title 130
Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide
###end article-title 130
###begin article-title 131
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
###end article-title 131
###begin article-title 132
Reversal of the Swedish familial Alzheimer's disease mutant phenotype in cultured cells treated with phorbol 12,13-dibutyrate
###end article-title 132
###begin article-title 133
Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons
###end article-title 133
###begin article-title 134
APP processing and synaptic function
###end article-title 134
###begin article-title 135
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient for the amyloid precursor protein gene
###end article-title 135
###begin article-title 136
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family memebers
###end article-title 136
###begin article-title 137
A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60
###end article-title 137
###begin article-title 138
Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein
###end article-title 138
###begin article-title 139
Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha
###end article-title 139
###begin article-title 140
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ras</italic>
###xml 95 110 <span type="species:ncbi:10090">transgenic mice</span>
Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
###end article-title 140
###begin article-title 141
Actin' up: RhoB in cancer and apoptosis
###end article-title 141
###begin article-title 142
Regulated cleavage of Alzheimer beta-amyloid precursor protein in the absence of the cytoplasmic tail
###end article-title 142
###begin article-title 143
Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: A potential role in regulated shedding
###end article-title 143
###begin article-title 144
Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein
###end article-title 144
###begin article-title 145
###xml 54 59 <span type="species:ncbi:9606">human</span>
Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and proteinkinase
###end article-title 145
###begin article-title 146
Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-Golgi network
###end article-title 146
###begin article-title 147
Amyloidogenesis in Alzheimer's disease: Some possible therapeutic opportunities
###end article-title 147
###begin article-title 148
###xml 114 119 <span type="species:ncbi:10090">mouse</span>
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model
###end article-title 148
###begin article-title 149
###xml 61 76 <span type="species:ncbi:10090">transgenic mice</span>
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice
###end article-title 149
###begin article-title 150
Alzheimer's disease: An inflammatory drug prospect
###end article-title 150
###begin article-title 151
Benefit of atorvastatin in the treatment of Alzheimer disease
###end article-title 151
###begin article-title 152
HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier
###end article-title 152
###begin article-title 153
Current concepts and future prospects for Alzheimer disease vaccines
###end article-title 153
###begin article-title 154
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein
###end article-title 154
###begin title 155
Abbreviations
###end title 155
###begin p 156
a disintegrin and metalloproteinase
###end p 156
###begin p 157
APP intracellular domain
###end p 157
###begin p 158
Alzheimer amyloid-beta peptide precursor protein
###end p 158
###begin p 159
amyloid-beta peptide
###end p 159
###begin p 160
constitutively active
###end p 160
###begin p 161
cell-surface Alzheimer amyloid-beta peptide precursor protein
###end p 161
###begin p 162
dominant negative
###end p 162
###begin p 163
extracellular-signal-regulated protein kinase
###end p 163
###begin p 164
farnesyl transferase inhibitor
###end p 164
###begin p 165
green fluorescent protein
###end p 165
###begin p 166
protein kinase C
###end p 166
###begin p 167
phenylarsine oxide
###end p 167
###begin p 168
Rho-associated protein kinase
###end p 168
###begin p 169
alpha-secretase-cleaved soluble Alzheimer amyloid-beta peptide precursor protein ectodomain
###end p 169
###begin p 170
transforming growth factor alpha
###end p 170
###begin p 171
tumor necrosis factor alpha
###end p 171
###begin title 172
Figures and Tables
###end title 172
###begin title 173
###xml 27 32 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Atorvastatin Activates sAPPalpha Shedding Out of Proportion to Its Effect on holoAPP or csAPP
###end title 173
###begin p 174
###xml 256 261 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
(A) SweAPP N2a cells were treated with atorvastatin (Atv) for 24 h and then surface biotinylation was performed as described in Methods. Evaluation of csAPP was performed by immunoprecipitation-immunoblot after surface biotinylation, while holoAPP and sAPPalpha were evaluated by immunoblot as described in Methods. C, control.
###end p 174
###begin p 175
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 199 200 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 219 220 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
(B) Graphic representation of data. Y-axis shows effect of treatment (in arbitrary units) divided by effect of untreated control (in arbitrary units); n = 3 independent experiments; *, p < 0.05; **, p < 0.01; Student's t test).
###end p 175
###begin title 176
###xml 109 114 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Simultaneous Treatment of SweAPP N2a Cells with Statins and an Inhibitor of Endocytosis (PO) Yields More sAPPalpha Shedding Than Does Treatment with Either Statins or PO Alone
###end title 176
###begin p 177
###xml 289 294 285 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
(A) SweAPP N2a cells were treated for 24 h with atorvastatin (Atv) or simvastatin (Sim) as indicated. Media were then replaced and cells were treated for an additional 20 min with atorvastatin, simvastatin, TNFalpha protease inhibitor, PO, or combinations, as indicated. Evaluation of sAPPalpha and holoAPP was performed by Western blot as described in Methods. C, control.
###end p 177
###begin p 178
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 214 215 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 236 237 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 321 322 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
(B) Graphic representation of data. Y-axis shows effect of treatment (in arbitrary units) divided by effect of untreated control (in arbitrary units); n = 3 independent experiments; *, p < 0.05 versus control; **, p < 0.01 versus C; #, p < 0.05 versus atorvastatin alone; ##, p < 0.05 versus simvastatin alone; Student's t test).
###end p 178
###begin title 179
###xml 86 91 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Simultaneous Treatment of SweAPP N2a Cells with a Statin and FTI-1 Causes Greater sAPPalpha Shedding Than Either Drug Alone
###end title 179
###begin p 180
###xml 171 176 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
(A) SweAPP N2a cells were treated for 24 h with atorvastatin (Atv, 5 muM), simvastatin (Sim, 1 muM), FTI-1 (5 muM), or a combination of FTI-1 plus a statin. Levels of sAPPalpha (top panel) or holoAPP (bottom panel) were evaluated as described in Methods. C, control.
###end p 180
###begin p 181
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 214 215 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 255 256 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 300 301 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
(B) Graphic representation of data. Y-axis shows effect of treatment (in arbitrary units) divided by effect of untreated control (in arbitrary units); n = 3 independent experiments; *, p < 0.05 versus control; **, p < 0.05 versus atorvastatin alone; ***, p < 0.05 versus simvastatin alone; Student's t test).
###end p 181
###begin title 182
###xml 67 72 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Mevalonic Acid Reverses Statin-Induced, but Not FTI-1-Induced, sAPPalpha Shedding
###end title 182
###begin p 183
###xml 157 162 154 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
SweAPP N2a cells were treated for 24 h with simvastatin (Sim, 1 muM), FTI-1 (5 muM), mevalonic acid (0-100 muM), or combinations as indicated. Levels of sAPPalpha were evaluated by western blot as described in Methods. This figure is representative of the results of two independent experiments. C, control.
###end p 183
###begin title 184
###xml 92 97 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Structure and Expression of ROCK cDNAs, and Their Effect on Basal and Statin-Stimulated sAPPalpha Shedding
###end title 184
###begin p 185
(A) Graphic representation of the ROCK1 constructs. Myc, Myc tag; KD, kinase domain; PH domain, pleckstrin homology domain; RBD, Rho-binding domain.
###end p 185
###begin p 186
(B) SweAPP N2a cells were transfected with GFP, CA ROCK1, or DN ROCK1 for 48 h. Cells were lysed and levels of expressed ROCK1 protein evaluated by immunoprecipitation-immunoblot as described in Methods.
###end p 186
###begin p 187
(C) Model for ROCK activity modulation by Rho.
###end p 187
###begin p 188
###xml 204 209 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
(D) SweAPP N2a cells were transfected for 48 h with control (GFP), CA ROCK1, or DN ROCK1 cDNAs. At the end of this incubation, cells were treated for an additional 24 h with simvastatin (Sim, 1 muM). sAPPalpha and holoAPP were evaluated by immunoblot as described in Methods.
###end p 188
###begin p 189
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 216 217 216 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
(E) Graphic representation of data. Y-axis shows effect of treatment (in arbitrary units) divided by effect of untreated control (in arbitrary units); n = 3 independent experiments; *, p < 0.05 versus GFP; Student's t test). C, control.
###end p 189
###begin title 190
###xml 36 41 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
Arachidonic Acid Inhibits Basal sAPPalpha Shedding but Has No Effect on holoAPP Levels
###end title 190
###begin p 191
###xml 133 138 132 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
(A) SweAPP cells were treated for 24 h with arachidonic acid (5 or 50 muM, represented by AA5 and AA50, respectively). Levels of sAPPalpha were evaluated by immunoblot as described in Methods. C, control.
###end p 191
###begin p 192
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
(B) Graphic representation of data. Y-axis shows effect of treatment (in arbitrary units) divided by effect of untreated control (in arbitrary units); n = 6 independent experiments; *, p < 0.05 versus control; Student's t test.
###end p 192
###begin title 193
Isoprenoid Pathway and Sites of Action of Compounds Used in This Study
###end title 193
###begin p 194
FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate.
###end p 194
###begin p 195
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Citation:</bold>
Citation: Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, et al. (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2(1): e18.
###end p 195

